Histone deacetylases, including sirtuin 6 (SIRT6) and histone deacetylase 11 (HDAC11), can promote glycolysis by suppressing the expression of intermediate signaling molecules, which in turn contributes to targeted therapy resistance in cancer cells [26, 194]. This evidence concerns the gene SIRT6 and cancer.